



## OPEN

# Noncanonical Wnt5a enhances Wnt/ $\beta$ -catenin signaling during osteoblastogenesis

## SUBJECT AREAS:

DIFFERENTIATION  
MORPHOGEN SIGNALLING  
BONE DEVELOPMENTMasanori Okamoto<sup>1</sup>, Nobuyuki Udagawa<sup>2</sup>, Shunsuke Uehara<sup>2</sup>, Kazuhiro Maeda<sup>3</sup>, Teruhito Yamashita<sup>4</sup>, Yuko Nakamichi<sup>4</sup>, Hiroyuki Kato<sup>1</sup>, Naoto Saito<sup>5</sup>, Yasuhiro Minami<sup>6</sup>, Naoyuki Takahashi<sup>4</sup> & Yasuhiro Kobayashi<sup>4</sup>Received  
29 October 2013Accepted  
12 March 2014Published  
27 March 2014

Correspondence and requests for materials should be addressed to Y.K. (ykoba@po.mdu.ac.jp)


<sup>1</sup>Department of Orthopaedic Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan, <sup>2</sup>Department of Biochemistry, Matsumoto Dental University, 1780 Hiro-oka Gobara, Shiojiri, Nagano 399-0781, Japan, <sup>3</sup>Department of Orthopaedic Surgery, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo 105-8641, Japan, <sup>4</sup>Institute for Oral Science, Matsumoto Dental University, 1780 Hiro-oka Gobara, Shiojiri, Nagano 399-0781, Japan, <sup>5</sup>Department of Applied Physical Therapy, Shinshu University School of Health Sciences, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan, <sup>6</sup>Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan.

**Wnt regulates bone formation through  $\beta$ -catenin-dependent canonical and -independent noncanonical signaling pathways. However, the cooperation that exists between the two signaling pathways during osteoblastogenesis remains to be elucidated. Here, we showed that the lack of *Wnt5a* in osteoblast-lineage cells impaired Wnt/ $\beta$ -catenin signaling due to the reduced expression of *Lrp5* and *Lrp6*. Pretreatment of ST2 cells, a stromal cell line, with *Wnt5a* enhanced canonical Wnt ligand-induced Tcf/Lef transcription activity. Short hairpin RNA-mediated knockdown of *Wnt5a*, but not treatment with *Dkk1*, an antagonist of Wnt/ $\beta$ -catenin signaling, reduced the expression of *Lrp5* and *Lrp6* in osteoblast-lineage cells under osteogenic culture conditions. Osteoblast-lineage cells from *Wnt5a*-deficient mice exhibited reduced Wnt/ $\beta$ -catenin signaling, which impaired osteoblast differentiation and enhanced adipocyte differentiation. Adenovirus-mediated gene transfer of *Lrp5* into *Wnt5a*-deficient osteoblast-lineage cells rescued their phenotypic features. Therefore, *Wnt5a*-induced noncanonical signaling cooperates with Wnt/ $\beta$ -catenin signaling to achieve proper bone formation.**

Wnt signaling plays critical roles in the development, growth, and homeostasis of various organs including the skeletal system<sup>1–4</sup>. The binding of Wnt to receptor complexes activates  $\beta$ -catenin-dependent canonical and  $\beta$ -catenin-independent noncanonical signaling pathways<sup>5</sup>.

In the absence of Wnt, a complex of APC, axin, and glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ) phosphorylates  $\beta$ -catenin. Phosphorylated  $\beta$ -catenin subsequently undergoes ubiquitination and degradation. Canonical Wnt such as Wnt3a binds to the receptor complex of Frizzled (Fzd) and low density lipoprotein receptor-related protein 5 (Lrp5) or Lrp6. This complex inhibits the kinase activity of GSK-3 $\beta$ , which in turn induces the accumulation of  $\beta$ -catenin in the target cells. The accumulation of  $\beta$ -catenin leads to its translocation into the nucleus, where it interacts with T-cell factor/lymphoid enhancer factor (Tcf/Lef) family members to initiate the transcription of target genes. TAZ, a transcription factor for the hippo pathway, has also recently been shown to function as an inducer for osteoblastogenesis and a suppressor for adipogenesis during canonical Wnt signaling<sup>6</sup>. On the other hand, *Wnt5a* binds to the receptor complex of Fzd, Ror1/2 or Ryk, and activates  $\beta$ -catenin-independent non-canonical signaling including Wnt/Ca<sup>2+</sup> and Wnt/planar cell polarity pathways<sup>7</sup>.

The importance of Lrp5 in bone formation was exemplified by identification of mutations within the *LRP5* gene of patients with osteoporosis-pseudoglioma syndrome (OPPG)<sup>8</sup>. The number of osteoblasts and bone mass in *Lrp5*<sup>-/-</sup> mice was reduced<sup>9</sup>. Lrp5 signaling in the duodenum was shown to regulate bone formation by inhibiting serotonin synthesis<sup>10</sup>. The findings of the study indicated that Lrp5 may function in the gut to regulate bone mass. However, the following studies highlighted us of the importance of Lrp5 in osteoblast-lineage cells. Mice with the osteocyte-specific, but not gut-specific expression of a gain-of-function mutant of *Lrp5* (G171V or A214V) exhibited a high bone mass associated with an increase in bone formation<sup>11</sup>. Lrp5 signaling is recently reported to promote bone formation through direct reprogramming of glucose metabolism in osteoblasts<sup>12</sup>. These



**Figure 1 | Wnt5a-induced noncanonical signals regulate the expression of Lrp5 and Lrp6.** (A–D) The effects of Wnt5a on canonical Wnt ligand-induced Tcf/Lef activity in ST2 cells. The Tcf/Lef-EGFP reporter was stably expressed in ST2 cells. After culturing with 200 ng/ml of Wnt5a or vehicle for 24 hours, ST2 cells were washed with  $\alpha$ -MEM and further cultured for 48 hours in the presence or absence of 100 ng/ml Wnt ligands. EGFP-positive cells were counted. (A) Micrographs of ST2 cell cultures. Scale bar, 30  $\mu$ m. (B, D) Number of EGFP-positive cells per 10,000 cells. (C) Western blot analysis of ST2 cell cultures. ST2 cells were cultured using the same method as described above. (E) Effects of Dkk1 on *Lrp5/6* expression in calvarial cells. Calvarial cells were cultured for the indicated time in the presence or absence of 1  $\mu$ g/ml Dkk1. The expression of *Alpl*, *Lrp5/6* mRNA was detected using real-time PCR. (F) Effects of the shRNA-mediated knockdown of *Wnt5a* on *Lrp5/6* expression in calvarial cells. shRNAs were transfected into calvarial cells using retrovirus. After the transfection, calvarial cells were cultured for 10 days in osteogenic medium. The expression of *Lrp5/6* mRNA was detected. In (B, D–F), data are expressed as the mean  $\pm$  SD ( $n = 3$ ). \* $p < 0.05$ , \*\* $p < 0.01$ , n.s.; not significant. In (C), the full length blots were presented in Supplementary Fig. S5.

findings suggest that Lrp5 signaling is important for the regulation of bone formation. However, the regulation of Lrp5 and Lrp6 expression in osteoblasts has not been fully elucidated.

Wnt5a-induced noncanonical Wnt signaling has been shown to suppress adipogenesis, which, in turn, promotes the differentiation of mesenchymal stem cells into osteoblast lineage cells<sup>13</sup>. *Wnt5a*<sup>+/-</sup> mice exhibited a low bone mass with increased adipogenesis and decreased osteoblastogenesis. Wnt5a suppressed Ppar- $\gamma$  transactivation by a co-repressor complex through calcium-calmodulin-dependent protein kinase II-TGF- $\beta$  activated kinase 1-Nemo-like kinase signaling and induced the expression of Runx2, leading to promotion of osteoblastogenesis<sup>13</sup>. Moreover, osteoblast-lineage cell-specific *Wnt5a*-deficient mice (*Wnt5a* cKO) exhibited a low bone mass with decreased bone formation<sup>14</sup>. Thus, noncanonical Wnt signals also promote osteoblastogenesis. These previous studies have indicated that both canonical and noncanonical Wnt signalings are required for proper bone formation. However, there is little information about how these two signaling pathways might cooperate with each other during osteoblastogenesis.


Here we showed that Wnt5a-induced noncanonical signaling promoted osteoblast differentiation through the up-regulation of Lrp5 and Lrp6. Osteoblast-lineage cells from the calvariae of *Wnt5a*<sup>-/-</sup> mice showed impaired mineralization due to the decreased expression of Lrp5 and Lrp6. The overexpression of Lrp5 in *Wnt5a*<sup>-/-</sup> calvarial cells rescued their phenotypes. Thus, Wnt5a induced the up-regulation of Lrp5 and Lrp6, which promoted osteoblast differentiation by canonical Wnt protein-mediated signaling.

## Results

**Pretreatment with Wnt5a enhances Wnt/ $\beta$ -catenin signaling.** Using bone marrow stromal ST2 cells, in which the Tcf/Lef-EGFP reporter was stably expressed, we found that pretreatment of ST2 cells with Wnt5a enhanced Wnt3a-induced EGFP expression while Wnt5a failed to induce EGFP expression (Fig. 1, A and B). Western blot analysis confirmed that the pretreatment with Wnt5a enhanced Wnt3a-induced EGFP expression and also the Wnt3a-induced accumulation of cytosolic  $\beta$ -catenin in ST2 cells (Fig. 1C). This pretreatment also enhanced Wnt/ $\beta$ -catenin signaling induced by canonical Wnt ligands such as Wnt7a, Wnt9b, and Wnt10b in ST2 cells (Fig. 1D).

**Expression of Wnt, Wnt co-receptors, and Fzd during osteoblast differentiation.** The above findings prompted us to clarify the roles of Wnt5a in the enhancement of Wnt/ $\beta$ -catenin signaling during osteoblastogenesis. We examined the expression of Wnt ligands such as Wnt5a, Wnt7b, and Wnt10b in calvarial cells under osteogenic culture conditions (Supplementary Fig. S1A online). The expression of *Wnt5a* and *Wnt10b* mRNA, but not *Wnt7b* mRNA was increased in these cultures. Consistently, Wnt5a and Wnt10b, but not Wnt7b, protein levels were increased in these cultures in a time-dependent manner (Supplementary Fig. S1B).

We next examined the expression of Wnt receptors in those cells. The expression of Lrp5 and Lrp6, but not *Ror2* or *Ryk*, was increased in calvarial cells during osteoblast differentiation (Supplementary Fig. S1C). Western blot analysis revealed that the expression of



**Figure 2 | Wnt5a-deficient calvarial cells exhibit impaired osteoblastogenesis associated with a reduction in *Lrp5* and *Lrp6* expression.** (A) The expression of *Lrp5* and *Lrp6* in wild-type (WT) and *Wnt5a*<sup>-/-</sup> calvarial cells. Calvarial cells were cultured in osteogenic medium and subjected to real-time PCR analysis. (B) Western blot analysis of *Lrp5/6* expression in WT and *Wnt5a*<sup>-/-</sup> calvarial cells. Cells were cultured using the same method as that described in (A). The full length blots were presented in Supplementary Fig. S5. (C) Cytochemical staining for alkaline phosphatase activity (top, blue) and alizarin red S staining (bottom, red) in WT and *Wnt5a*<sup>-/-</sup> calvarial cell cultures in osteogenic medium in the presence of BMP2 (200 ng/ml). (D, E) The expression of osteoblastic transcription factors (D) and marker genes (E) in WT and *Wnt5a*<sup>-/-</sup> calvarial cell cultures. Cells were cultured using the same method as that described in (A). In (A, C–E), data are expressed as the mean  $\pm$  SD ( $n = 3$ ). \* $p < 0.05$ , \*\* $p < 0.01$ .

*Lrp5* and *Lrp6* was increased in these calvarial cell cultures (Supplementary Fig. S1D). These results suggest that the expression of *Lrp5* and *Lrp6* is increased in calvarial cells during osteoblast differentiation.

The expression of *Lrp5* and *Lrp6* in calvarial cells was increased with increasing expression of Wnt ligands such as *Wnt10b* and *Wnt5a*. To clarify the roles of Wnt/ $\beta$ -catenin signaling in the up-regulation of *Lrp5* and *Lrp6* in calvarial cells, Dickkopf1 (*Dkk1*), which disrupts Wnt/*Lrp5* or *Lrp6* interactions to inhibit Wnt/ $\beta$ -catenin<sup>15</sup> and Wnt/TAZ signals<sup>6</sup>, was added to calvarial cell cultures, and the expression of *Lrp5* and *Lrp6* was examined (Fig. 1E). The expression of *Alpl* (encoding alkaline phosphatase), a marker of osteoblasts, was increased during osteoblastogenesis. The treatment of calvarial cells with *Dkk1* suppressed the expression of *Alpl*, but not that of *Lrp5* or *Lrp6*. These results indicate that canonical Wnt signals do not promote the expression of *Lrp5/6* in calvarial cells.

Therefore, we examined whether noncanonical Wnt5a regulates *Lrp5* and *Lrp6* expression in calvarial cells using short hairpin-RNA-mediated knockdown of *Wnt5a* in calvarial cells. The suppression of *Wnt5a* expression led to the reduced expression of *Lrp5* and *Lrp6* (Fig. 1F).


**Wnt5a regulates *Lrp5/6* expression.** To confirm the up-regulation of *Lrp5/6* expression by Wnt5a in calvarial cells, we examined their expressions in *Wnt5a*<sup>-/-</sup> calvarial cells compared with wild-type cells. The expression of *Lrp5/6* was significantly lower in *Wnt5a*<sup>-/-</sup> cells ( $n = 3$ ,  $P = 0.00003$ ) (Fig. 2A). The expression levels of the *Lrp5* and *Lrp6* proteins in *Wnt5a*<sup>-/-</sup> cells was lower than those in wild-type cells (Fig. 2B). These results suggest that Wnt5a positively regulates the expression of *Lrp5/6* in calvarial cells during their differentiation into osteoblasts.

*Wnt5a*<sup>-/-</sup> calvarial cells exhibited impaired mineralization, a criterion for osteoblast differentiation. Consistent with a previous study<sup>14</sup>, alkaline phosphatase activity and mineralization were significantly lower in *Wnt5a*<sup>-/-</sup> cells ( $n = 3$ ,  $P = 0.000000006$ ) (Fig. 2C). The expression of *Runx2* and *Sp7* (encoding Osterix),

transcription factors necessary for osteoblast differentiation<sup>16–18</sup>, was increased in wild-type calvarial cells under osteogenic culture conditions at day 10. However, the expression of these genes was lower in *Wnt5a*<sup>-/-</sup> cells (Fig. 2D). As expected, the expression of *Alpl*, *Col1a1* (encoding type I collagen  $\alpha 1$ ), and *Bglap1* (encoding osteocalcin), markers for osteoblasts, was also lower in *Wnt5a*<sup>-/-</sup> calvarial cells (Fig. 2E). These results suggest that osteoblast differentiation is impaired in *Wnt5a*<sup>-/-</sup> calvarial cells.

***Wnt5a*<sup>-/-</sup> calvarial cells exhibited impaired Wnt/ $\beta$ -catenin signaling.** Experiments using *Wnt5a*<sup>-/-</sup> calvarial cells indicated that endogenous Wnt5a up-regulated the expression of *Lrp5/6* in calvarial cells during osteoblastogenesis. Therefore, we examined whether Wnt/ $\beta$ -catenin signaling was impaired in *Wnt5a*<sup>-/-</sup> calvarial cells. The expression of *Axin2*, a target gene of Wnt/ $\beta$ -catenin signaling, was decreased in *Wnt5a*<sup>-/-</sup> calvarial cells (Fig. 3A). We further confirmed impaired Wnt/ $\beta$ -catenin signaling in *Wnt5a*<sup>-/-</sup> calvarial cells using adenoviral-mediated gene transfers of the Super-TOP-DsRed reporter (Supplementary Fig. S2). The number of DsRed-positive cells was significantly lower in *Wnt5a*<sup>-/-</sup> calvarial cells treated with Wnt3a ( $n = 4$ ,  $P = 0.002$ ) (Fig. 3B) and under osteogenic conditions without any exogenous Wnt proteins (Fig. 3C). Western blot analysis revealed that the expression level of  $\beta$ -catenin was lower in *Wnt5a*<sup>-/-</sup> calvarial cells than in wild-type cells at day 10 (Fig. 3D). Immunohistochemical analysis revealed that the protein level of  $\beta$ -catenin in bone-lining osteoblasts was lower in the scapulae from *Wnt5a*<sup>-/-</sup> mice (Fig. 3E). Western blot analysis also confirmed that the expression level of  $\beta$ -catenin in the scapula of *Wnt5a*<sup>-/-</sup> mice was lower than that in the scapula of wild-type mice (Fig. 3F). These results indicate that Wnt/ $\beta$ -catenin signaling is impaired in *Wnt5a*<sup>-/-</sup> osteoblast-lineage cells.

We next examined the effects of exogenous Wnt5a on osteoblastogenesis in *Wnt5a*<sup>-/-</sup> calvarial cells. The treatment of these cells with Wnt5a enhanced the expression of *Lrp5* and *Lrp6* (Fig. 4A), but failed to increase the expression of *Axin2* mRNA at day 5, and this may have been due to the insufficient expression of endogenous



**Figure 3** | Wnt5a-deficient calvarial cells exhibit impaired Wnt/ $\beta$ -catenin signals. (A) The expression of *Axin2* in wild-type (WT) and *Wnt5a*<sup>-/-</sup> calvarial cell cultures. Cells were cultured in osteogenic medium for the indicated time and subjected to real-time PCR analysis. (B, C) The number of DsRed-positive cells in WT and *Wnt5a*<sup>-/-</sup> calvarial cell cultures transfected with the Tcf/Lef DsRed reporter adenovirus. In (B), cells were treated with Wnt3a (100 ng/ml) under growth culture conditions. In (C), cells were cultured under osteogenic conditions. (D) Western blot analysis of  $\beta$ -catenin expression in WT and *Wnt5a*<sup>-/-</sup> calvarial cells. Cells were cultured in osteogenic medium for 10 days. (E) Immunohistochemical staining (brown) of  $\beta$ -catenin in the scapulae of WT and *Wnt5a*<sup>-/-</sup> mice at E18.5. (F) Western blot analysis of  $\beta$ -catenin in the scapulae from WT and *Wnt5a*<sup>-/-</sup> mice at E18.5. Scale bar, 30  $\mu$ m. In (A–C), data are expressed as the mean  $\pm$  SD ( $n = 3$ –4). \* $p < 0.05$ , \*\* $p < 0.01$ , N.D.; not detected. In (D, F), the full length blots were presented in Supplementary Fig. S5.

canonical Wnt ligands at this time point. We, therefore, examined the effects of pretreatment with Wnt5a on Wnt3a-induced Wnt/ $\beta$ -catenin signaling in *Wnt5a*<sup>-/-</sup> calvarial cells. Similar to ST2 cell cultures (Fig. 1A), the pretreatment with Wnt5a enhanced Wnt3a-induced the expression of DsRed in those cultures (Fig. 4B). Western blot analysis confirmed that the pretreatment with Wnt5a increased the protein levels of Lrp5/6 in *Wnt5a*<sup>-/-</sup>, but not wild-type, calvarial cell cultures (Supplementary Fig. S3). These findings suggest that Wnt5a is abundantly secreted from wild-type calvarial cells in osteogenic medium, and that Wnt5a enhances expression of Lrp5/6 although Wnt5a does not directly activate Wnt/ $\beta$ -catenin signaling. Furthermore, treatments of *Wnt5a*<sup>-/-</sup> calvarial cells with Wnt5a rescued mineralization within 14 days (Fig. 4C).


To efficiently express Lrp5 in calvarial cells, we prepared an adenovirus possessing the full length of *Lrp5* cDNA. Real-time PCR and Western blot analysis confirmed the overexpression of *Lrp5* in calvarial cells (Fig. 4D and Supplementary Fig. S4A). Furthermore, a luciferase assay using the TOP-Flash reporter also confirmed that the overexpression of *Lrp5* enhanced Wnt3a-induced Tcf/Lef activity in calvarial cells (Supplementary Fig. S4B). Adenovirus-mediated gene transfer of *Lrp5* into *Wnt5a*<sup>-/-</sup> cells rescued the Tcf/Lef activity (Fig. 4E) and the mineralization (Fig. 4F). These results suggest that Wnt5a promotes osteoblastogenesis through the expression of Lrp5 and Lrp6.

We have previously shown that adipogenesis was enhanced in *Wnt5a*<sup>-/-</sup> calvarial cell cultures, even under osteogenic culture conditions<sup>14</sup>. We next investigated whether the overexpression of *Lrp5* suppressed adipogenesis in *Wnt5a*<sup>-/-</sup> calvarial cells. The number of adipocytes was significantly decreased in *Wnt5a*<sup>-/-</sup> calvarial cell cultures in which Lrp5 was expressed ( $n = 3$ ,  $P = 0.01$ ) (Fig. 4G). The percentage of ZsGreen-positive adipocytes (indicating an adenoviral infection) was lower in *Wnt5a*<sup>-/-</sup> calvarial cell cultures infected with the *Lrp5*-adenovirus (Fig. 4H). These results suggest that Wnt5a suppresses adipogenic differentiation in calvarial cells through the up-regulation of Lrp5 and Lrp6.

**Effects of Sp7 on the expression of Lrp5/6.** We attempted to identify the possible mechanism by which Wnt5a enhanced Lrp5/6 expression in calvarial cells (Fig. 5). Using the TRANSFAC retrieval program, we searched for putative transcription binding sites on the 2.0-kb *Lrp5* promoter and 2.0-kb *Lrp6* promoter, and found that both promoters contained putative Sp1 binding sites (Fig. 5A). Sp7 was previously shown to bind to Sp1-binding sites<sup>17</sup>. The expression of Sp7 was significantly lower in *Wnt5a*<sup>-/-</sup> calvarial cells (see Fig. 2D). These results suggest that Sp7 may up-regulate Lrp5/6 expression during osteoblast differentiation. The chromatin immunoprecipitation assay showed that Sp1 already bound the proximal Sp1 sites on the *Lrp5* and *Lrp6* promoters in wild-type calvarial cells. Sp7 was recruited to the proximal Sp1 sites on the *Lrp5* promoter within 2 days, while the recruitment of Sp1 was decreased on the proximal Sp1 sites during the culture period. We previously reported that c-Jun was recruited to Sp1 sites on the *tnfrsf11a* promoter under Wnt5a-Ror2 signaling<sup>14</sup>. However, the recruitment of c-Jun was not observed on the proximal Sp1 sites on the *Lrp5* promoter (data not shown). The recruitment of Sp1, but not Sp7, was increased on the proximal Sp1 sites on the *Lrp6* promoter (Fig. 5A). These results suggest that Lrp5 expression may be regulated by Sp7 in calvarial cells.

We next examined whether the overexpression of Sp7 up-regulated Lrp5 expression in calvarial cells (Fig. 5B). The adenovirus-mediated gene transfer of *Sp7* into wild-type calvarial cells increased the expression of the Lrp5 protein.

Bone morphogenetic protein 2 (BMP2) was previously reported to induce Sp7 expression in C2C12 cells<sup>19</sup>. Wnt5a enhanced BMP2 signals in C2C12 cells<sup>20</sup>. Therefore, we examined the effects of Wnt5a and BMP2 on the expression of Sp7 in *Wnt5a*<sup>-/-</sup> calvarial cells (Fig. 5C). Although Wnt5a by itself failed to induce the expression of Sp7 in calvarial cells, Wnt5a enhanced the BMP2-induced expression of Sp7. These results suggested that BMP2 and Wnt5a co-operatively regulate Sp7 expression in calvarial cells.



**Figure 4 | Treatment with Wnt5a or the expression of *Lrp5* rescues the phenotypic features of *Wnt5a*<sup>-/-</sup> calvarial cells.** (A) The effect of Wnt5a on the expression of *Lrp5*, *Lrp6* and *Axin2* in *Wnt5a*<sup>-/-</sup> calvarial cells. Cells were cultured in the presence of Wnt5a (500 ng/ml) under osteogenic conditions and subjected to real-time PCR analysis. (B) Effects of the pretreatment with Wnt5a on Wnt3a-induced Wnt/ $\beta$ -catenin signaling in *Wnt5a*<sup>-/-</sup> calvarial cells. Cells transfected with the Tcf/Lef DsRed reporters were treated with Wnt5a (500 ng/ml) or vehicle for 5 days and further cultured for 48 hours with or without Wnt3a (100 ng/ml). (C) The effect of Wnt5a on mineralization in *Wnt5a*<sup>-/-</sup> calvarial cells. Cells were cultured in the presence of Wnt5a (500 ng/ml) plus BMP2 (200 ng/ml) under osteogenic conditions for 14 days. (D) The expression of *Lrp5* in *Wnt5a*<sup>-/-</sup> calvarial cells infected with LacZ- and Lrp5-adenovirus. After the adenovirus-mediated gene transfer of *Lrp5*, cells were further cultured for 1 day. (E) The number of DsRed-positive cells in wild-type (WT) and *Wnt5a*<sup>-/-</sup> calvarial cells infected with LacZ- and Lrp5-adenovirus together with the Tcf/Lef DsRed reporter adenovirus. After adenovirus-mediated gene transfer, cells were cultured in osteogenic medium for 10 days. (F) The effect of the adenoviral-gene transfer of *Lrp5* or *LacZ* on mineralization in *Wnt5a*<sup>-/-</sup> calvarial cell cultures. After adenovirus-mediated gene transfer, cells were cultured using the same method as that described in (C). (G) The number of adipocytes in *Wnt5a*<sup>-/-</sup> calvarial cell cultures infected with LacZ- and Lrp5-adenovirus. Cells having oil droplets stained with oil Red O were counted as adipocytes. (H) The percent of ZsGreen-positive cells in total adipocytes. The transfection of *Lrp5* and *LacZ* cDNA, and cell cultures were performed according to the described method in (G). Upper and lower photographs show the expression of ZsGreen and cytochemical staining with oil Red O, respectively. Scale bar, 15  $\mu$ m. In (B), (E), and (G), Ds-Red-positive cells or adipocytes were counted, and number of DsRed-positive cells or adipocytes was adjusted to the total cell number and expressed per 10,000 cells. In (A–H), data are expressed as the mean  $\pm$  SD ( $n > 3$ ). \* $p < 0.05$ , \*\* $p < 0.01$ , n.s.; not significant, N.D.; not detected.


We finally examined the involvement of Ror2 co-receptors in *Lrp5/6* expression in calvarial cells. Real-time-PCR analysis revealed that the expression of *Lrp5/6* in *Ror2*<sup>-/-</sup> calvarial cells was similar to that in wild-type calvarial cells (Fig. 5D). We previously demonstrated that mineralized nodule formations commonly occurred in *Ror2*<sup>-/-</sup> calvarial cell cultures<sup>14</sup>. These results suggest that Ror2 co-receptors were not involved in *Lrp5/6* expression in osteoblastogenesis.

## Discussion

In this study, we demonstrated that noncanonical Wnt5a up-regulated the expression of *Lrp5/6* in osteoblast-lineage cells, which

promoted osteoblastogenesis and inhibited adipogenesis via Wnt/ $\beta$ -catenin signaling.

Several lines of evidence have shown that Wnt5a antagonizes Wnt/ $\beta$ -catenin signaling through the Wnt/ $\text{Ca}^{2+}$  pathway<sup>21</sup> and  $\beta$ -catenin degradation by seven in absentia homolog 2, an E3 ubiquitin ligase<sup>22</sup>. Wnt5a was shown to compete with Wnt3a for binding to Fzd2, which mediates Wnt5a- and Wnt3a-induced signals<sup>23</sup>. Wnt/ $\beta$ -catenin signaling was consistently lower in HEK293 cells treated with Wnt3a and Wnt5a than in cultures treated with Wnt3a (data not shown). On the other hand, pretreatment of ST2 cells with Wnt5a enhanced canonical Wnt ligand-induced Wnt/ $\beta$ -catenin signaling. Not only the expression of *Wnt10b*, *Lrp5*, and *Lrp6*, but also the



**Figure 5 | Wnt5a and BMP2 cooperatively enhance Lrp5 expression through Sp7 in calvarial cells.** (A) Chromatin immunoprecipitation assay of the *Lrp5* and *Lrp6* genes in wild-type calvarial cells. Calvarial cells were cultured in osteogenic medium for the indicated time and subjected to ChIP analysis. Upper schemas show the promoter of the *Lrp5* and *Lrp6* genes. Putative Sp1 binding sites were indicated. E1; exon 1. Asterisks indicate non-specific bands. The full length gels were presented in Supplementary Fig. S5. (B) Effects of Sp7 on Lrp5 expression in wild-type calvarial cells. After the adenovirus-mediated gene transfer of *LacZ* (Control) or *Sp7* cDNA, cells were cultured in osteogenic medium for 2 days and subjected to Western blot analysis. The full length blots were presented in Supplementary Fig. S5. (C) Effects of Wnt5a and BMP2 on *Sp7* expression in *Wnt5a*<sup>-/-</sup> calvarial cells. Cells were cultured in the presence or absence of Wnt5a (200 ng/ml) with or without BMP2 (100 ng/ml). The expression of *Sp7* mRNA was examined in these cultures. \**p* < 0.05, \*\**p* < 0.01 (D) The expression of *Lrp5* and *Lrp6* mRNA in *Ror2*<sup>-/-</sup> calvarial cells. Wild-type (WT) and *Ror2*<sup>-/-</sup> calvarial cells were cultured under osteogenic conditions and subjected to real-time PCR analysis. In (C, D), data are expressed as the mean ± SD (*n* = 3).

expression of *Wnt5a* was increased during osteoblastogenesis. Wnt/ $\beta$ -catenin signaling, as detected by the expression of DsRed protein, was higher in wild-type calvarial cells than in *Wnt5a*<sup>-/-</sup> cells under osteogenic culture conditions. Therefore, our results suggest that *Wnt5a* is not just an inhibitor of Wnt/ $\beta$ -catenin signaling, but rather enhances it. We and others have shown that osteoblast differentiation in *Wnt5a*<sup>+/-</sup> and osteoblast-lineage-specific *Wnt5a* conditional knockout mice was impaired<sup>13,14</sup>. Thus, *Wnt5a* is involved in osteoblast differentiation by the up-regulating *Lrp5/6*.

Wu et al.<sup>24</sup> have shown that *Wnt3a* activated *Rac1*-c-Jun N-terminal kinase2 pathway, a noncanonical Wnt signaling, which can promote the nuclear accumulation of  $\beta$ -catenin. Noncanonical Wnt signaling controls Wnt/ $\beta$ -catenin signaling, which is involved in the development of limb skeletons. In contrast, Wnt/ $\beta$ -catenin signaling is not involved in the up-regulation of *Lrp5/6* since *Dkk1* failed to inhibit their expression during osteoblast differentiation. Thus, the present study provides a novel finding that *Wnt5a*-induced noncanonical signaling up-regulated *Lrp5/6* expression in osteoblast-lineage cells to increase their sensitivity for canonical Wnt ligands. Thus, *Wnt5a* regulates osteoblast differentiation in collaboration with canonical Wnt ligands such as *Wnt3a* and *Wnt10b*.

By using mice crossing *tetO-Wnt5a*; *Rosa26rtTA*-double transgenic mice (in which *Wnt5a* is expressed by the administration of doxycycline) with reporter mice (in which *lacZ* is expressed under

the *Axin2* promoter), *Wnt5a* was shown to activate Wnt/ $\beta$ -catenin signaling in the developing skull, especially the meninges, although the calvarial bone of these mice exhibited impaired ossification<sup>25</sup>. On the other hand, Wnt/ $\beta$ -catenin signaling was reduced in their skin. These findings indicate that *Wnt5a* can both activate and inhibit Wnt/ $\beta$ -catenin signaling in a tissue- and temporal-specific manner. We have previously shown that *Wnt5a* was highly expressed in calvarial cells under growth culture conditions, and its expression was further increased under osteogenic culture conditions<sup>14</sup>. Our present study showed that *Wnt5a* promoted Wnt/ $\beta$ -catenin signaling during osteoblast differentiation. Thus, *Wnt5a* signals modulate a receptor context of the cells to properly respond to canonical Wnt ligands during osteoblastogenesis.

*Wnt5a* has been shown to bind a receptor complex of *Fzd4* and *Lrp5* and activate Wnt/ $\beta$ -catenin signaling in HEK293 cells, in which *Fzd4* and *Lrp5* were overexpressed<sup>26</sup>. Our observation of the increased expression of *Wnt5a*, *Lrp5*, and *Lrp6* during osteoblastogenesis implies that *Wnt5a* by itself may activate Wnt/ $\beta$ -catenin signaling through *Lrp5* or *Lrp6*. However, the overexpression of *Lrp5* in *Wnt5a*<sup>-/-</sup> calvarial cells enhanced Wnt/ $\beta$ -catenin signaling. Moreover, the expression of *Fzd4* in calvarial cells was not increased in osteogenic medium (data not shown). Based on these findings, it is unlikely that *Wnt5a* directly binds to a receptor complex of *Lrp5* and *Fzd4* and activates Wnt/ $\beta$ -catenin signaling in calvarial cells.



Endogenous Wnt ligands such as Wnt10b may activate Wnt/ $\beta$ -catenin signaling in these cells under osteogenic conditions.

Wnt5a was shown to activate noncanonical Wnt signaling in a Ror receptor-dependent manner<sup>27,28</sup>. We previously showed that *Ror2*<sup>+/-</sup> mice failed to exhibit impaired bone formation, and mineralization was indeed normal in calvarial cell cultures isolated from *Ror2*<sup>-/-</sup> mice<sup>14</sup>. Furthermore, the present study showed that the expression of *Lrp5/6* in *Ror2*<sup>-/-</sup> calvarial cells was similar to that in wild-type cells. These results indicate that Ror2-mediated signaling is not involved in the Wnt5a-induced up-regulation of *Lrp5/6* in osteoblast-lineage cells.

In the present study, we demonstrated that Sp7 may be involved in the enhanced expression of *Lrp5* by Wnt5a in calvarial cells for the following reasons. First, the expression of *Lrp5* was lower in *Wnt5a*<sup>-/-</sup> calvarial cells with a reduction in the expression of Sp7. Second, Sp7 was recruited to Sp1 binding sites on the proximal *Lrp5* promoter in calvarial cells in osteogenic medium. Third, the over-expression of Sp7 enhanced *Lrp5* expression in calvarial cells. Fourth, Wnt5a enhanced BMP2-induced expression of *Sp7* mRNA in calvarial cells, but not Wnt5a by itself. These results indicated that Wnt5a and BMP2 may co-operatively regulate *Lrp5* expression in calvarial cells. This is important for osteoblast lineage cells to activate Wnt/ $\beta$ -catenin signaling effectively in conditions that canonical Wnt ligands work. Thus, Wnt5a may regulate osteoblast differentiation in collaboration with BMP2 as well as canonical Wnt ligands. Further studies are needed to clarify how Wnt5a enhances *Lrp6* expression and enhances BMP2 signaling during osteoblast differentiation.

Wnt/ $\beta$ -catenin signaling was shown to inhibit the differentiation of stromal cells into adipocytes through the suppression of *Cebp/α* and *Ppar-γ* expression<sup>29,30</sup>. Wnt5a also inhibited adipogenesis through the suppression of transcriptional activity of *Ppar-γ*<sup>13</sup>. The number of adipocytes was higher in the bone marrow from 20-week-old *Wnt5a*<sup>+/-</sup> mice. We previously reported that calvarial cells from *Wnt5a*<sup>-/-</sup> mice preferably differentiated into adipocytes<sup>14</sup>. *Ex vivo* experiments showed that the enforced expression of *Lrp5* suppressed adipogenesis in *Wnt5a*<sup>-/-</sup> calvarial cell cultures by promoting Wnt/ $\beta$ -catenin signaling. Thus, Wnt5a suppresses adipogenesis through two mechanisms, suppression of the transcriptional activity of *Ppar-γ* and an enhancement in Wnt/ $\beta$ -catenin signaling through *Lrp5/6* expression. TAZ has also been shown to function as an inducer for osteoblastogenesis and a suppressor for adipogenesis during canonical Wnt signaling<sup>6</sup>. Thus, it can be envisaged that Wnt5a enhances Wnt/ $\beta$ -catenin and Wnt/TAZ signals through the up-regulation of *Lrp5/6* during osteoblast differentiation.

We showed that Wnt5a autonomously regulated the expression of *Lrp5* and *Lrp6*, which promoted Wnt/ $\beta$ -catenin signaling during osteoblast differentiation. This signaling axis was also critical for the suppression of adipogenesis. Thus, Wnt5a regulates osteoblastogenesis and adipogenesis through the up-regulation of Wnt/ $\beta$ -catenin signaling.

## Methods

**Mice and reagents.** *Wnt5a*<sup>+/-</sup> mice were maintained as described previously<sup>31</sup>. *Ror2*<sup>+/-</sup> mice were maintained as described previously<sup>32</sup>. In *in vitro* experiments, cells isolated from embryos were used regardless of their gender. All procedures using mice were approved by the Animal Management Committee of Matsumoto Dental University. All experiments using mice were performed in accordance with the guidelines of the Animal Management Committee of Matsumoto Dental University. Recombinant mouse Wnt5a, Wnt3a, Wnt7a, Wnt 9b and Wnt10b were purchased from R&D systems Co. Ltd. (Minneapolis, MN). Chemicals and reagents used in this study were of analytical grade.

**Cell cultures.** Calvarial cells were prepared from the calvariae of *Wnt5a*<sup>-/-</sup> and wild-type embryos at E18.5 as described previously<sup>14</sup>. Cells were maintained in  $\alpha$ -MEM with 10% fetal bovine serum (growth culture conditions). To induce osteoblastic differentiation, cells ( $2 \times 10^4$  cells/cm<sup>2</sup>) were cultured in osteogenic medium containing 5 mM  $\beta$ -glycerophosphate and 100  $\mu$ g/ml ascorbic acid (osteogenic culture conditions) with or without 200 ng/ml BMP2 (R&D systems) using collagen-coated plates. Approximately 2 weeks after the cultivation, cells were fixed. These cells were stained with alizarin red S or stained for alkaline phosphatase activity as

described previously<sup>33</sup>. Mineralized area (%) in wells was calculated using NIH image software. Confluent calvarial cells were cultured for RNA analysis for the indicated time in osteogenic medium.

*Wnt5a*<sup>-/-</sup> calvarial cells were cultured for 10 days in the presence or absence of 500 ng/ml of recombinant mouse Wnt5a, and used for the subsequent analysis.

ST2 cells were cultured for 24 hours in the presence or absence of 200 ng/ml of recombinant mouse Wnt5a. Cells were washed with fresh culture medium and further cultured for 48 hours in the presence of 100 ng/ml of Wnt3a, Wnt7a or Wnt10b.

**PCR and Real time PCR.** Total RNA was isolated from calvarial cells using RNA isolation kits (PureLink RNA mini kit, Life Technology, Carlsbad, CA) and RNase-free DNase I (Qiagen, Hilden, Germany). cDNA synthesis was performed on 1–2  $\mu$ g of total RNA using reverse transcriptase (Revtra Ace; Toyobo, Tokyo, Japan) and oligo dT primers. All PCR products were verified by direct DNA sequencing. Real time PCR was performed using SYBR Green Master Mixes (Life Technologies) with the StepOnePlus system (Life Technologies) as described previously<sup>14</sup>. Briefly, mRNA levels were calculated by normalizing to the house keeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using the  $\Delta$ CT method. Changes in gene expression of samples were expressed relative to that of untreated samples. Sequences of the primers used for PCR and real-time PCR analyses are described in Supplementary Table S1 online.

**Adenovirus-mediated gene transfer.** Full length *Lrp5* cDNA, full length *Sp7* cDNA (Thermo Scientific Open Biosystems, Yokohama, Japan), the 8xTcf/Lef promoter, and DsRed cDNA were amplified using high fidelity DNA polymerases (PrimeSTAR GXL, Takara Bio Inc, Otsu, Japan). PCR fragments of *Lrp5* and of 8xTcf/Lef-DsRed were ligated into adenoviral vectors pAdenoX-ZsGreen1 and pAdenoX-PRLS-ZsGreen1, respectively (Takara Bio Inc). The linearized vectors were transfected into HEK293T cells to produce an adenovirus according to the manufacturers' instructions. Purified adenoviruses were infected into cells at a dose of 50–100 multiplicity of infection (MOI). cDNA fragments were amplified using the following primers. *Lrp5* forward; acgacatggaacggcgccga, *Lrp5* reverse; tcaggacgagtcgctgagg, *Sp7* forward; atggcctctctctgctga, *Sp7* reverse; atcagatgtgtagcagga, 8xTcf/Lef promoter forward; gtaactacatcgtcgtctcca, 8xTcf/Lef promoter reverse; cggaatgccaagctttttac, DsRed forward; tttagtgaacctgagatcc, DsRed reverse; tgagtttggacaaccacaac.

**Tcf/Lef reporter cells.** Lentivirus (Signal Lenti reporter with Tcf/Lef binding sites, Qiagen, Hilden, Germany) was infected into ST2 cells at a dose of 50 MOI. To select stable clones expressing the reporter, cells were treated with 2  $\mu$ g/ml puromycin dihydrochloride (Sigma, St Louis, MO). Resistant colonies were used for subsequent experiments.

**Immunohistochemical and immunoblotting studies.** Paraffin sections of the scapulae from wild-type and *Wnt5a*<sup>-/-</sup> embryo at E18.5 were subjected to immunostaining using anti- $\beta$ -catenin antibodies (R&D systems). Immunocomplexes were visualized with diaminobenzidine (Dako). The sections were counterstained with hematoxylin.

Western blot analyses were performed using anti-GFP (Abcam) and anti- $\beta$ -catenin (Cell Signaling Technology), anti- $\beta$ -actin (Sigma), anti-Wnt5a (R&D Systems), Anti-Wnt7b (Santa Cruz), Anti-Wnt10b (Abcam), Anti-Lrp5 (Cell Signaling Technology), anti-Lrp6 (Abcam) antibodies as described previously<sup>14</sup>. Lysates (40  $\mu$ g protein/lane) from cells and from scapulae of E18.5 mice embryos were electrophoresed on SDS-PAGE gels, transferred to polyvinylidene difluoride membranes, and subjected to immunoblotting using the ECL plus chemiluminescence detection system (GE Healthcare, Buckinghamshire, UK).

**Chromatin immunoprecipitation (ChIP) assay.** ChIP was performed with the ChIP Assay kit (Upstate Biotechnology), using antibodies against Sp7 (Abcam), Sp1 (Santa Cruz), c-Jun (Cell Signaling Technology) and normal IgG (Santa Cruz) as described previously<sup>14</sup>. The purified DNA was analyzed by PCR using following primers PCR1 forward; cctctgagtgctgggatta, PCR1 reverse; agagatgggactgtcttcg, PCR2 forward; acgtgctcagtttctcac, PCR2 reverse; cagtcagcaccagcagcag on the *Lrp5* and PCR1 forward; cgagaggaagaggctgaatg, PCR1 reverse; cctcaactctcagcagcac, on the *Lrp6* promoter.

**shRNA-mediated knock down.** Retroviral vectors expressing short hairpin RNA against mouse Wnt5a (pSIREN-shRNA against Wnt5a) were constructed by inserting double-stranded oligonucleotides of the target into pSIREN (Clontech). Retroviral packaging was performed by transfection of plasmids into Plat-E cells as described previously<sup>14</sup>. Calvarial cells were incubated for 48 hours with virus-containing supernatants from Plat-E cultures, and used for real-time PCR analysis. The target sequences of Wnt5a are described. sh-Wnt5a#1; 5'CGUAGAGAA-AGGGAACGAAU3', sh-Wnt5a#2; 5'CCACUUGUAUCAGGACCACAU3'.

**Statistical analyses.** All cell culture experiments were performed at least three times and similar results were obtained. Statistical analysis of the data was performed by the Student's *t* test.

1. Baron, R. & Kneissel, M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. *Nat. Med.* **19**, 179–192 (2013).



2. Krishnan, V., Bryant, H. U. & Macdougald, O. A. Regulation of bone mass by Wnt signaling. *J. Clin. Invest.* **116**, 1202–1209 (2006).
3. Lories, R. J., Corr, M. & Lane, N. E. To Wnt or not to Wnt: the bone and joint health dilemma. *Nat. Rev. Rheumatol.* **9**, 328–339 (2013).
4. Nusse, R. & Varmus, H. E. Wnt genes. *Cell* **69**, 1073–1087 (1992).
5. Angers, S. & Moon, R. T. Proximal events in Wnt signal transduction. *Nat. Rev. Mol. Cell Biol.* **10**, 468–477 (2009).
6. Azzolin, L. *et al.* Role of TAZ as mediator of Wnt signaling. *Cell* **151**, 1443–1456 (2012).
7. Kikuchi, A., Yamamoto, H. & Sato, A. Selective activation mechanisms of Wnt signaling pathways. *Trends Cell Biol.* **19**, 119–129 (2009).
8. Gong, Y. *et al.* LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. *Cell* **107**, 513–523 (2001).
9. Kato, M. *et al.* Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. *J. Cell Biol.* **157**, 303–314 (2002).
10. Yadav, V. K. *et al.* Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. *Cell* **135**, 825–837 (2008).
11. Cui, Y. *et al.* Lrp5 functions in bone to regulate bone mass. *Nat. Med.* **17**, 684–691 (2011).
12. Esen, E. *et al.* WNT-LRP5 Signaling Induces Warburg Effect through mTORC2 Activation during Osteoblast Differentiation. *Cell Metab.* **17**, 745–755 (2013).
13. Takada, I. *et al.* A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR- $\gamma$  transactivation. *Nat. Cell Biol.* **9**, 1273–1285 (2007).
14. Maeda, K. *et al.* Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. *Nat. Med.* **18**, 405–412 (2012).
15. Mao, B. *et al.* Kremen proteins are Dickkopf receptors that regulate Wnt/ $\beta$ -catenin signalling. *Nature* **417**, 664–667 (2002).
16. Komori, T. *et al.* Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell* **89**, 755–764 (1997).
17. Nakashima, K. *et al.* The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. *Cell* **108**, 17–29 (2002).
18. Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L. & Karsenty, G. *Osf2/Cbfa1*: a transcriptional activator of osteoblast differentiation. *Cell* **89**, 747–754 (1997).
19. Ulsamer, A. *et al.* BMP-2 induces Osterix expression through up-regulation of *Dlx5* and its phosphorylation by p38. *J. Biol. Chem.* **283**, 3816–3826 (2008).
20. Nakashima, A. *et al.* Cross-talk between Wnt and Bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts. *J. Biol. Chem.* **280**, 37660–37668 (2005).
21. Ishitani, T. *et al.* The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/ $\beta$ -catenin signaling. *Mol. Cell Biol.* **23**, 131–139 (2003).
22. Topol, L. *et al.* Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent  $\beta$ -catenin degradation. *J. Cell Biol.* **162**, 899–908 (2003).
23. Sato, A., Yamamoto, H., Sakane, H., Koyama, H. & Kikuchi, A. Wnt5a regulates distinct signalling pathways by binding to Frizzled2. *EMBO J.* **29**, 41–54 (2010).
24. Wu, X. *et al.* Rac1 activation controls nuclear localization of  $\beta$ -catenin during canonical Wnt signaling. *Cell* **133**, 340–353 (2008).
25. van Amerongen, R., Fuerer, C., Mizutani, M. & Nusse, R. Wnt5a can both activate and repress Wnt/ $\beta$ -catenin signaling during mouse embryonic development. *Dev. Biol.* **369**, 101–114 (2012).
26. Mikels, A. J. & Nusse, R. Purified Wnt5a protein activates or inhibits  $\beta$ -catenin-TCF signaling depending on receptor context. *PLoS Biol.* **4**, e115 (2006).
27. Oishi, I. *et al.* The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. *Genes Cells* **8**, 645–654 (2003).
28. Minami, Y., Oishi, I., Endo, M. & Nishita, M. Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases. *Dev. Dyn.* **239**, 1–15 (2010).
29. Ross, S. E. *et al.* Inhibition of adipogenesis by Wnt signaling. *Science* **289**, 950–953 (2000).
30. Bennett, C. N. *et al.* Regulation of osteoblastogenesis and bone mass by Wnt10b. *Proc. Natl. Acad. Sci. USA* **102**, 3324–3329 (2005).
31. Yamaguchi, T. P., Bradley, A., McMahon, A. P. & Jones, S. A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. *Development* **126**, 1211–1223 (1999).
32. Takeuchi, S. *et al.* Mouse Ror2 receptor tyrosine kinase is required for the heart development and limb formation. *Genes Cells* **5**, 71–78 (2000).
33. Tu, X. *et al.* Noncanonical Wnt signaling through G protein-linked PKC $\delta$  activation promotes bone formation. *Dev. Cell* **12**, 113–127 (2007).

## Acknowledgments

This work was supported by Japan Society for the Promotion of Science (JSPS, Kakenhi) [Grant number; 25221310 (N.T.), 25293423 (Y.K.), 24390417 (N.U.), 24241045 (N.S.)], and by a grant from Naito Foundation Natural Science (Y.K.).

## Author contributions

M.O. conducted most of the experiments and prepared the manuscript. K.M., T.Y. and S.U. supported the *in vitro* experiments. N.U., Y.N., H.K., N.S. and Y.M. contributed the data analysis. Y.K. designed and supervised the project. N.T. and Y.K. wrote the manuscript.

## Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Okamoto, M. *et al.* Noncanonical Wnt5a enhances Wnt/ $\beta$ -catenin signaling during osteoblastogenesis. *Sci. Rep.* **4**, 4493; DOI:10.1038/srep04493 (2014).



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported license. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0>